Spero is a product-focused biopharmaceutical company developing a pipeline of novel treatments for bacterial infections, specifically targeting gram-negative bacterial infections. The company enhances existing drugs through its Spero Potentiator program and targets bacterial virulence and persistence with its MvfR inhibitor program.
Market
Bacterial Infections
Location
Cambridge,
Massachusetts,
USA
Coinvestors
Atlas Venture, Kraft Group, Lundbeckfond Ventures, Merck Research Labs Venture Fund, Partners Innovation Fund, SR One